Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease

Journal of Managed Care and Specialty Pharmacy

Volumn 24, Issue 3, 2018, Pages 280-290

  Mehta, Sandhya ^a   Ghosh, Sabyasachi ^b   Sander, Stephen ^b   Kuti, Effie ^b   Mountford, William K ^a  

^a Cambridge ^*  (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ELECTRONIC MEDICAL RECORD; EMERGENCY WARD; FOLLOW UP; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRESCRIPTION; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PATIENT ATTITUDE; RETROSPECTIVE STUDY; TRENDS;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 85042556883     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2018.24.3.280     Document Type: Article

References (41)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64-S71. Available at: http://care. diabetesjournals.org/content/35/Supplement_1/S64.full.pdf+html. Accessed January 31, 2018
2. American Diabetes Association. Statistics about diabetes. 2014. Available at: http://www.diabetes.org/diabetes-basics/statistics/. Accessed January 31, 2018
3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012 Diabetes Care. 2013;36(4):1033-46
5. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-81
7. Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of Cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52-60
8. Bennett KE, Williams D, Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol. 2003;58(12):835-41
9. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292
10. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053-59
11. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134-46
12. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96(9):3248-50
13. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care. 1991;14(7):639-48
14. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203
15. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102
16. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6
17. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med. 2008;359(15):1577-89
18. Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4-5
19. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care. 2002;25(3):482-86
20. Ariza MA, Vimalananda VG, Rosenzweig JL. The economic consequences of diabetes and cardiovascular disease in the United States. Rev Endocr Metab Disord. 2010;11(1):1-10
21. Glauber H, Brown J. Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol. 1994;47(10):1133-42
22. Garis RI, Shara MA, Farmer KC, Horrell JF, Arora M. The cost of diabetes in the presence of comorbid conditions. Manag Care Interface. 2002;15(4):48-53, 55
23. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics. 1999;16(3):285-95
24. Simpson SH, Corabian P, Jacobs P, Johnson JA. The cost of major comorbidity in people with diabetes mellitus. CMAJ. 2003;168(13):1661-67
25. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45(7):S13-17
26. Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diabetes Complications. 2007;21(2):75-83
27. Huse DM. Expanding the evidence base in outcomes research: linking electronic medical records and claims data. A case study examining risk factors and costs of uncontrolled hypertension. Presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA. Available at: https://www.ispor.org/meetings/neworleans0513/releasedpresentations/W26-Durden. pdf. Accessed January 31, 2018
28. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-360
29. Yat Wa L, Wilbert SA. Diabetes mellitus and cardiovascular disease. J Clinic Experiment Cardiol. 2011;2(1):114. Available at: https://www.omicsonline. org/diabetes-mellitus-and-cardiovascular-disease-2155-9880.1000114. pdf. Accessed January 31, 2018
30. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available at: http://www.bls.gov/cpi. Accessed January 31, 2018
31. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-82
32. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29(3):725-31
33. Slater M, Perruccio AV, Badley EM. Musculoskeletal comorbidities in cardiovascular disease, diabetes and respiratory disease: the impact on activity limitations; a representative population-based study. BMC Public Health. 2011;11:77
34. American Association of Clinical Endocrinologists, Diabetes Resource Center. Management of common comorbidities of diabetes. Available at: http://outpatient.aace.com/type-2-diabetes/management-of-common-comorbidities-of-diabetes. Accessed January 31, 2018
35. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the U.S. in 2002 Diabetes Care. 2003;26(3):917-32
36. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care. 2009;32(12):2187-92
37. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 1998;21(7):1122-28
38. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med. 2003;348(5):383-93
39. Luft VC, Giugliani C, Harzheim E, Schmidt MI, Duncan BB. Prevalence of use and potential impact of increased use of primary care interventions to prevent cardiovascular hospitalizations in patients with diabetes. Diabetes Res Clin Pract. 2009;85(3):328-34
40. Fraze T, Jiang J, Burgess J. Hospital stays for patients with diabetes, 2008 Statistical Brief #93. Healthcare Cost and Utilization Project (H-CUP). August 2010. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb93.pdf. Accessed January 31, 2018
41. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3(5):356-66